-
公开(公告)号:US20210403862A1
公开(公告)日:2021-12-30
申请号:US17195385
申请日:2021-03-08
Applicant: The Scripps Research Institute
Inventor: Yue Xu , Sheng Ding
IPC: C12N5/0735 , C07D239/48 , C07D277/56 , C07D401/14 , C07D403/04 , C07D417/12 , C07D417/14 , C07D401/04
Abstract: The present invention relates compounds for stabilizing cells and methods of their use.
-
公开(公告)号:US09695395B2
公开(公告)日:2017-07-04
申请号:US14490433
申请日:2014-09-18
Applicant: The Scripps Research Institute
Inventor: Wenlin Li , Sheng Ding
IPC: C12N5/00 , C12N5/0735 , C12N5/074
CPC classification number: C12N5/0606 , C12N5/0696 , C12N2501/115 , C12N2501/16 , C12N2501/2306 , C12N2501/235 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/727 , C12N2510/00
Abstract: The present invention provides for the generation and maintenance of pluripotent cells by culturing the cells in the presence of an ALK5 inhibitor.
-
公开(公告)号:US20160264938A1
公开(公告)日:2016-09-15
申请号:US15072769
申请日:2016-03-17
Applicant: The Scripps Research Institute
Inventor: Jem A. Efe , Janghwan Kim , Saiyong Zhu , Simon Hilcove , Sheng Ding
IPC: C12N5/0797 , C12N5/074 , C12N5/077
CPC classification number: C12N5/0676 , A61K35/30 , A61K35/33 , A61K35/34 , A61K35/39 , C12N5/0602 , C12N5/0603 , C12N5/0607 , C12N5/0618 , C12N5/0619 , C12N5/0623 , C12N5/0657 , C12N5/0678 , C12N15/85 , C12N2501/01 , C12N2501/155 , C12N2501/235 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/605 , C12N2501/606 , C12N2501/727 , C12N2506/02 , C12N2506/08 , C12N2506/1307 , C12N2510/00
Abstract: The present invention generally provides methods and compositions for transdifferentiation of an animal cell from a first non-pluripotent cell fate to a second non-pluripotent cell fate. Also provided are methods and compositions for the transdifferentiation of an animal cell from a non-pluripotent mesodermal, endodermal, or ectodermal cell fate to a different non-pluripotent mesodermal, endodermal, or ectodermal cell fate.
Abstract translation: 本发明通常提供了用于将动物细胞从第一非多能细胞命运转化为第二非多能细胞命运的方法和组合物。 还提供了用于将动物细胞从非多能中胚层,内胚层或外胚层细胞命运转分化成不同的非多能中胚层,内胚层或外胚层细胞命运的方法和组合物。
-
公开(公告)号:US20140273214A1
公开(公告)日:2014-09-18
申请号:US14188616
申请日:2014-02-24
Applicant: The Scripps Research Institute
Inventor: Yue Xu , Sheng Ding
IPC: C07D401/04
CPC classification number: C12N5/0606 , C07D239/48 , C07D277/56 , C07D401/04 , C07D401/14 , C07D403/04 , C07D417/12 , C07D417/14 , C12N2501/999
Abstract: The present invention relates compounds for stabilizing cells and methods of their use.
Abstract translation: 本发明涉及用于稳定细胞的化合物及其使用方法。
-
公开(公告)号:US12195762B2
公开(公告)日:2025-01-14
申请号:US17320676
申请日:2021-05-14
Applicant: The Scripps Research Institute
Inventor: Tongxiang Lin , Sheng Ding
IPC: C12N5/074
Abstract: The slow kinetics and low efficiency of reprogramming methods to generate human induced pluripotent stem cells (iPSCs) impose major limitations on their utility in biomedical applications. Here we describe a chemical approach that dramatically improves (>200 fold) the efficiency of iPSC generation from human fibroblasts, within seven days of treatment. This will provide a basis for developing safer, more efficient, non-viral methods for reprogramming human somatic cells.
-
公开(公告)号:US10738281B2
公开(公告)日:2020-08-11
申请号:US16239452
申请日:2019-01-03
Applicant: The Scripps Research Institute
Inventor: Saiyong Zhu , Sheng Ding
IPC: C12N5/074
Abstract: The present invention provides for methods, compositions, and kits for producing an induced pluripotent stem cell from a non-pluripotent mammalian cell using a 3′-phosphoinositide-dependent kinase-1 (PDK1) activator or a compound that promotes glycolytic metabolism as well as other small molecules.
-
公开(公告)号:US20190203182A1
公开(公告)日:2019-07-04
申请号:US16239452
申请日:2019-01-03
Applicant: The Scripps Research Institute
Inventor: Saiyong Zhu , Sheng Ding
IPC: C12N5/074
CPC classification number: C12N5/0696 , C12N2501/065 , C12N2501/15 , C12N2501/41 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/606 , C12N2501/727 , C12N2501/73 , C12N2506/03 , C12N2506/094 , C12N2506/28
Abstract: The present invention provides for methods, compositions, and kits for producing an induced pluripotent stem cell from a non-pluripotent mammalian cell using a 3′-phosphoinositide-dependent kinase-1 (PDK1) activator or a compound that promotes glycolytic metabolism as well as other small molecules.
-
公开(公告)号:US10214729B2
公开(公告)日:2019-02-26
申请号:US15489600
申请日:2017-04-17
Applicant: The Scripps Research Institute
Inventor: Saiyong Zhu , Sheng Ding
IPC: C12N5/074
Abstract: The present invention provides for methods, compositions, and kits for producing an induced pluripotent stem cell from a non-pluripotent mammalian cell using a 3′-phosphoinositide-dependent kinase-1 (PDK1) activator or a compound that promotes glycolytic metabolism as well as other small molecules.
-
公开(公告)号:US09909105B2
公开(公告)日:2018-03-06
申请号:US14637089
申请日:2015-03-03
Applicant: The Scripps Research Institute
Inventor: Tongxiang Lin , Sheng Ding
CPC classification number: C12N5/0696 , C12N2501/065 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/606 , C12N2501/727 , C12N2501/999 , C12N2506/094 , C12N2506/1307 , C12N2506/28 , C12N2510/00
Abstract: The slow kinetics and low efficiency of reprogramming methods to generate human induced pluripotent stem cells (iPSCs) impose major limitations on their utility in biomedical applications. Here we describe a chemical approach that dramatically improves (>200 fold) the efficiency of iPSC generation from human fibroblasts, within seven days of treatment. This will provide a basis for developing safer, more efficient, non-viral methods for reprogramming human somatic cells.
-
公开(公告)号:US09896655B2
公开(公告)日:2018-02-20
申请号:US15098546
申请日:2016-04-14
Applicant: The Scripps Research Institute
Inventor: Yue Xu , Sheng Ding
IPC: C12N5/0735 , C07D239/48 , C07D277/56 , C07D401/04 , C07D401/14 , C07D403/04 , C07D417/12 , C07D417/14
CPC classification number: C12N5/0606 , C07D239/48 , C07D277/56 , C07D401/04 , C07D401/14 , C07D403/04 , C07D417/12 , C07D417/14 , C12N2501/999
Abstract: The present invention relates compounds for stabilizing cells and methods of their use.
-
-
-
-
-
-
-
-
-